301108.SZ
Tongling Jieya Biologic Technology Co., Ltd.
SZSE · C 制造业 · CN
CNY 46.97
−0.45%Year over year
Reported trailing growth
- Revenue
- +55.2%
- EBITDA
- —
- EBIT
- +340.7%
- EPS
- +198.5%
- Free cash flow
- —
- Operating cash flow
- +144.2%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.0%
- EBITDA
- -13.9%
- EBIT
- -20.4%
- Net income
- -18.2%
- EPS
- -26.9%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026